We use cookies to improve your experience on this website. Read More Allow Cookies

Novartis' Migrain Drug close to Approval

05 June, 2018

The new migraine targeting drug received key European approval and could be fully approved for use by the end of the year.

Aimovig® which prevents migraines has received approval from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). This almost definitely means approval by the European Union and could be available in Europe by the end of the year.

In the clinical programme, half of those with episodic migraine (four to 14 monthly migraine days) taking Aimovig had their number of migraine days cut by half or more. Those with chronic migraine (at least 15 monthly migraine days) achieved a similar, statistically significant response.

Aimovig works by blocking the activity of calcitonin gene-related peptide (CGRP), a molecule that is involved in migraine attacks.

Read more HERE